The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Sputum and serum calprotectin are useful biomarkers during CF exacerbation
Abstract
BACKGROUND Adequate monitoring of cystic fibrosis lung disease is difficult. CF exacerbation offers a unique setting to test the utility of biomarkers in the assessment of changing airways inflammation. We hypothesised that levels of calprotectin in sputum (and serum) would change informatively following treatment of an exacerbation. METHODS 27 patients with CF were recruited at onset of pulmonary exacerbation. Sputum and serum were collected at the start and end of anti-biotic therapy. Sputum calprotectin, interleukin-8 (IL8), and myeloperoxidase (MPO) were measured, as were serum calprotectin, CRP and vascular endothelial growth factor (VEGF). RESULTS Sputum calprotectin decreased following treatment of an exacerbation (p<0.05), and was superior to other sputum markers. Serum calprotectin, CRP, and VEGF also decreased significantly (p=0.002, p=0.002, p=0.013 respectively). Serum calprotectin level following treatment had predictive value for time to next exacerbation (p=0.032). CONCLUSIONS This study demonstrates the superiority of calprotectin (in sputum and serum) as a biomarker of CF exacerbation over better-established markers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Prior work has shown that CP accumulates as CF lung infection progresses and its levels correlate with disease severity (55, 56).”
From Heme protects Pseudomonas aeruginosa and Staphylococcus aureus from calprotectin-induced iron starvation (2021) · cites this paper as [55]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vogl, T., Tenbrock, K., Ludwig, S., Leukert, N., Ehrhardt, C., van Zoelen, M. A. D., Nacken, W., Foell, D., van der Poll, T., Sorg, C., et al. (2007) · Nature Medicine · doi:10.1038/nm1638 · Cited by 1,418
Research works printed but not linked: 41
- Boucher, 2004, New concepts of the pathogenesis of cystic fibrosis lung disease, Eur Respir J, 23, 146, 10.1183/09031936.03.00057003 · DOI · Paper page
- Goss, 2007, Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis, Thorax, 62, 360, 10.1136/thx.2006.060889 · DOI · Paper page
- Hiatt, 1999, Effects of viral lower respiratory tract infection on lung function in infants with cystic fibrosis, Pediatrics, 103, 619, 10.1542/peds.103.3.619 · DOI · Paper page
- Aaron, 2004, Adult cystic fibrosis exacerbations and new strains of Pseudomonas aeruginosa, Am J Respir Crit Care Med, 169, 811, 10.1164/rccm.200309-1306OC · DOI
- Smith, 1988, Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosis, J Pediatr, 112, 547, 10.1016/S0022-3476(88)80165-3 · DOI
- Ordonez, 2003, Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis, Am J Respir Crit Care Med, 168, 1471, 10.1164/rccm.200306-731OC · DOI · Paper page
- Colombo, 2005, Cytokine levels in sputum of cystic fibrosis patients before and after antibiotic therapy, Pediatr Pulmonol, 40, 15, 10.1002/ppul.20237 · DOI
- Marshall, 2004, Pulmonary exacerbations in cystic fibrosis: it's time to be explicit!, Am J Respir Crit Care Med, 169, 781, 10.1164/rccm.2401009 · DOI
- Fuchs, 1994, Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group, N Engl J Med, 331, 637, 10.1056/NEJM199409083311003 · DOI · Paper page
- Ramsey, 1999, Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group, N Engl J Med, 340, 23, 10.1056/NEJM199901073400104 · DOI · Paper page
- Rabin, 2004, Pulmonary exacerbations in cystic fibrosis, Pediatr Pulmonol, 37, 400, 10.1002/ppul.20023 · DOI · Paper page
- Sagel, 2001, Airway inflammation in children with cystic fibrosis and healthy children assessed by sputum induction, Am J Respir Crit Care Med, 164, 1425, 10.1164/ajrccm.164.8.2104075 · DOI · Paper page
- Sagel, 2002, Induced sputum inflammatory measures correlate with lung function in children with cystic fibrosis, J Pediatr, 141, 811, 10.1067/mpd.2002.129847 · DOI
- Salva, 1996, TNF-alpha, IL-8, soluble ICAM-1, and neutrophils in sputum of cystic fibrosis patients, Pediatr Pulmonol, 21, 11, 10.1002/(SICI)1099-0496(199601)21:1<11::AID-PPUL2>3.0.CO;2-T · doi:10.1002/(sici)1099-0496(199601)21:1<11::aid-ppul2>3.0.co;2-t
- Henig, 2001, Sputum induction as a research tool for sampling the airways of subjects with cystic fibrosis, Thorax, 56, 306, 10.1136/thorax.56.4.306 · doi:10.1136/thorax.56.4.306
- McGarvey, 2002, Cytokine concentrations and neutrophil elastase activity in bronchoalveolar lavage and induced sputum from patients with cystic fibrosis, mild asthma and healthy volunteers, J Cyst Fibros, 1, 269, 10.1016/S1569-1993(02)00098-X · DOI
- Sloane, 2005, Proteomic analysis of sputum from adults and children with cystic fibrosis and from control subjects, Am J Respir Crit Care Med, 172, 1416, 10.1164/rccm.200409-1215OC · doi:10.1164/rccm.200409-1215oc
- Regelmann, 1995, Sputum peroxidase activity correlates with the severity of lung disease in cystic fibrosis, Pediatr Pulmonol, 19, 1, 10.1002/ppul.1950190102 · DOI
- Meyer, 2004, Neutrophils, myeloperoxidase, and bronchiectasis in cystic fibrosis: green is not good, J Lab Clin Med, 144, 124, 10.1016/j.lab.2004.05.014 · DOI
- Ordonez, 2004, Variability of markers of inflammation and infection in induced sputum in children with cystic fibrosis, J Pediatr, 145, 689, 10.1016/j.jpeds.2004.06.054 · doi:10.1016/j.jpeds.2004.06.054
- Sagel, 2005, Induced sputum matrix metalloproteinase-9 correlates with lung function and airway inflammation in children with cystic fibrosis, Pediatr Pulmonol, 39, 224, 10.1002/ppul.20165 · DOI
- Downey, 2007, The relationship of clinical and inflammatory markers to outcome in stable patients with cystic fibrosis, Pediatr Pulmonol, 42, 216, 10.1002/ppul.20553 · DOI
- Mayer-Hamblett, 2007, Association between Pulmonary Function and Sputum Biomarkers in Cystic Fibrosis, Am J Respir Crit Care Med, 175, 822, 10.1164/rccm.200609-1354OC · DOI · Paper page
- Macgregor, 2008, Biomarkers for cystic fibrosis lung disease: Application of SELDI-TOF mass spectrometry to BAL fluid, J Cyst Fibros, 7, 352, 10.1016/j.jcf.2007.12.005 · DOI
- Gray, 2008, Sputum proteomics in inflammatory and suppurative respiratory diseases, Am J Respir Crit Care Med, 178, 444, 10.1164/rccm.200703-409OC · DOI · Paper page
- Wilson, 1975, Studies on cystic fibrosis using isoelectric focusing. I. An assay for detection of cystic fibrosis homozygotes and heterozygote carriers from serum, Pediatr Res, 9, 635, 10.1203/00006450-197508000-00005 · doi:10.1203/00006450-197508000-00005
- Dorin, 1987, A clue to the basic defect in cystic fibrosis from cloning the CF antigen gene, Nature, 326, 614, 10.1038/326614a0 · DOI · Paper page
- Raquil, 2008, Blockade of antimicrobial proteins S100A8 and S100A9 inhibits phagocyte migration to the alveoli in streptococcal pneumonia, J Immunol, 180, 3366, 10.4049/jimmunol.180.5.3366 · DOI
- Downey, 2007, The effect of treatment of cystic fibrosis pulmonary exacerbations on airways and systemic inflammation, Pediatr Pulmonol, 42, 729, 10.1002/ppul.20646 · DOI
- Reid, 2007, Oxidative stress and lipid-derived inflammatory mediators during acute exacerbations of cystic fibrosis, Respirology, 12, 63, 10.1111/j.1440-1843.2006.00962.x · doi:10.1111/j.1440-1843.2006.00962.x
- Rowe, 2008, Potential Role of High-Mobility Group Box 1 in Cystic Fibrosis Airway Disease, Am J Respir Crit Care Med, 178, 822, 10.1164/rccm.200712-1894OC · DOI
- McColley, 2000, Serum vascular endothelial growth factor is elevated in cystic fibrosis and decreases with treatment of acute pulmonary exacerbation, Am J Respir Crit Care Med, 161, 1877, 10.1164/ajrccm.161.6.9905022 · DOI
- Pizzichini, 1996, Measurement of inflammatory indices in induced sputum: effects of selection of sputum to minimize salivary contamination, Eur Respir J, 9, 1174, 10.1183/09031936.96.09061174 · DOI · Paper page
- Boussac, 2000, Calcium-dependent secretion in human neutrophils: a proteomic approach, Electrophoresis, 21, 665, 10.1002/(SICI)1522-2683(20000201)21:3<665::AID-ELPS665>3.0.CO;2-U · DOI
- Voganatsi, 2001, Mechanism of extracellular release of human neutrophil calprotectin complex, J Leukoc Biol, 70, 130, 10.1189/jlb.70.1.130 · DOI · Paper page
- Fagerhol, 2000, Calprotectin, a faecal marker of organic gastrointestinal abnormality, Lancet, 356, 1783, 10.1016/S0140-6736(00)03224-4 · DOI
- Costa, 2005, Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease, Gut, 54, 364, 10.1136/gut.2004.043406 · DOI · Paper page
- Cohen, 2005, Pathophysiologic consequences following inhibition of a CFTR-dependent developmental cascade in the lung, BMC Dev Biol, 5, 2, 10.1186/1471-213X-5-2 · DOI
- Husson, 2005, Effect of intermittent inhaled tobramycin on sputum cytokine profiles in cystic fibrosis, J Antimicrob Chemother, 56, 247, 10.1093/jac/dki179 · doi:10.1093/jac/dki179
- Ordonez, 2001, Effect of clarithromycin on airway obstruction and inflammatory markers in induced sputum in cystic fibrosis: a pilot study, Pediatr Pulmonol, 32, 29, 10.1002/ppul.1085 · DOI
- Watt, 2005, Neutrophil cell death, activation and bacterial infection in cystic fibrosis, Thorax, 60, 659, 10.1136/thx.2004.038240 · DOI
Cited by
Zygiel, E. M., Nelson, C. E., Brewer, L. K., Oglesby-Sherrouse, A. G., & Nolan, E. M. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.006819 · Cited by 76
Ye, Z., Ai, X., Liao, Z., You, C., & Cheng, Y. (2019) · Medicine · doi:10.1097/md.0000000000016371 · Cited by 57
Zygiel, E. M., Obisesan, A. O., Nelson, C. E., Oglesby, A. G., & Nolan, E. M. (2021) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.015975 · Cited by 36
Metadata
- Authors
- Gray, R. D., Imrie, M., Boyd, A. C., Porteous, D., Innes, J. A., & Greening, A. P.
- Venue
- Journal of Cystic Fibrosis
- Publisher
- Elsevier BV
- Published
- 2010-05
- Volume
- 9
- Issue
- 3
- Pages
- 193-198
- ISSN
- 1569-1993
- Cited by
- 135
- References
- 1
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 1172 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.